IP Library Granted Patent US 10,012,647
Granted Patent B2
US 10,012,647 · App. 14/799,942 · Granted Jul 3, 2018

Depletion of mouse cells for isolation of human cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,012,647
App. No.
14/799,942
Granted
Jul 3, 2018
Kind
B2
Abstract

A process for depleting host cells from a xenograft of human cells on a murine host is disclosed. The process includes fragmenting the xenograft, subjecting the sample to antibodies specific for a murine CD9 epitope coupled to a detection means, depleting the cell suspension from cells bound by the CD9-antibodies using the detection means, and collecting the cells not bound by the CD9-antibodies as target cells.

Claims (12)

1. A process for depleting host cells from a xenograft of human cells on a murine host, comprising:

a) fragmenting the xenograft into a sample comprising a single cell suspension

b) subjecting the sample to antibodies specific for a murine CD9 epitope coupled to a detection means

c) depleting the cell suspension from cells bound by the CD9 antibodies using the detection means

d) collecting the cells not bound by the CD9-antibodies;

e) subjecting the collected cells not bound by CD9 antibodies obtained in d) to antibodies specific for one or more murine epitopes selected from the group consisting of CD45, CD51, CD31, Ter119, CD24, EpCAM, Sca1, CD11b, CD95, H2Kk, H2Kd, and CD171, each coupled to a detection means, and

f) depleting the murine cells coupled to these antibodies to obtain human cells.

2. The process according to claim 1 , wherein the detection means of the antibodies is selected from the group consisting of magnetic particles, fluorescent dyes, and a solid support.

3. The process according to claim 1 , wherein the depletion of step c) is performed as at least one of magnetic separation, panning, and fluorescence activated cell sorting (FACS).

4. The process according to claim 1 , wherein mice are used as host.

5. The process according to claim 1 , wherein the human cells are human tumor cells.

6. The process according to claim 5 further comprising step g), the human cells obtained in step f) are subjected to antibodies specific for a human marker coupled to a detection means and further separated using the detection means into at least two fractions comprising distinct cell subpopulations.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 051443/0669 →